Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM)
Background: Advanced breast cancer (ABC) is an incurable disease, with a median overall survival (OS) of 3 years, even in high-income countries. Oncological treatment has improved survival rates, particularly for hormone receptor–positive and HER2-positive subtypes; however, access to new therapies...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Breast Cancer: Basic and Clinical Research |
| Online Access: | https://doi.org/10.1177/11782234251342477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850151318714318848 |
|---|---|
| author | Guillermo Valencia Patricia Rioja Olenka Peralta Miguel Chirito Raúl Mantilla Carlos Castañeda Zaida Morante Hugo Fuentes Tatiana Vidaurre Mónica Calderón Silvia Neciosup Henry L Gómez |
| author_facet | Guillermo Valencia Patricia Rioja Olenka Peralta Miguel Chirito Raúl Mantilla Carlos Castañeda Zaida Morante Hugo Fuentes Tatiana Vidaurre Mónica Calderón Silvia Neciosup Henry L Gómez |
| author_sort | Guillermo Valencia |
| collection | DOAJ |
| description | Background: Advanced breast cancer (ABC) is an incurable disease, with a median overall survival (OS) of 3 years, even in high-income countries. Oncological treatment has improved survival rates, particularly for hormone receptor–positive and HER2-positive subtypes; however, access to new therapies in Latin American (LATAM) countries is limited. Objectives: The impact of sequencing 2 lines of therapy in Peruvian patients with HER2-positive ABC in a single public institution was evaluated. First-line (1L) treatment consisted of trastuzumab and chemotherapy (CT, with taxanes), followed by second-line (2L) treatment with lapatinib plus capecitabine. Design: In this retrospective study, we analyze clínico-pathological features (including blood biomarkers) collected from medical records of patients with HER2-positive ABC treated in a public Peruvian oncologic institution and its association with survival between 2020 and 2022. Methods: Efficacy was measured using OS and progression-free survival (PFS). A discussion was added on the impact of OS based on clinicopathological characteristics, including outcomes in 2L “long-term responder” patients (who achieved response to 2L therapy ⩾6 months) and the evaluation of blood biomarkers. Results: Treatment sequencing has been demonstrated to enhance OS in patients with HER2-positive ABC, with a median OS of 34 months. This effect is more pronounced among long-term responders (37 months), particularly those without central nervous system (CNS) involvement, as compared with those with CNS metastases (51 vs 34 months). Blood biomarkers were not found to be prognostic indicators for either PFS or OS. Conclusions: Treatment sequencing has been demonstrated to enhance OS in LATAM patients with HER2-positive ABC. This study did not identify any prognostic blood biomarkers. These outcomes could influence the selection criteria for patients to receive treatment sequencing in countries without full access to innovative oncological therapies. |
| format | Article |
| id | doaj-art-8054448cc6b64739be3ad53fe0f4a4fc |
| institution | OA Journals |
| issn | 1178-2234 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Breast Cancer: Basic and Clinical Research |
| spelling | doaj-art-8054448cc6b64739be3ad53fe0f4a4fc2025-08-20T02:26:19ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342025-05-011910.1177/11782234251342477Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM)Guillermo Valencia0Patricia Rioja1Olenka Peralta2Miguel Chirito3Raúl Mantilla4Carlos Castañeda5Zaida Morante6Hugo Fuentes7Tatiana Vidaurre8Mónica Calderón9Silvia Neciosup10Henry L Gómez11Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, PeruGrupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, PeruMedical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, PeruMedical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, PeruFaculty of Natural Sciences and Mathematics, Universidad Nacional Federico Villarreal, Lima, PeruFaculty of Medicine, Universidad Científica del Sur, Lima, PeruGrupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, PeruFaculty of Medicine, Universidad de Piura, Piura, PeruMedical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, PeruFaculty of Medicine, Universidad Ricardo Palma, Lima, PeruGrupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, PeruFaculty of Medicine, Universidad Peruana Cayetano Heredia, Lima, PeruBackground: Advanced breast cancer (ABC) is an incurable disease, with a median overall survival (OS) of 3 years, even in high-income countries. Oncological treatment has improved survival rates, particularly for hormone receptor–positive and HER2-positive subtypes; however, access to new therapies in Latin American (LATAM) countries is limited. Objectives: The impact of sequencing 2 lines of therapy in Peruvian patients with HER2-positive ABC in a single public institution was evaluated. First-line (1L) treatment consisted of trastuzumab and chemotherapy (CT, with taxanes), followed by second-line (2L) treatment with lapatinib plus capecitabine. Design: In this retrospective study, we analyze clínico-pathological features (including blood biomarkers) collected from medical records of patients with HER2-positive ABC treated in a public Peruvian oncologic institution and its association with survival between 2020 and 2022. Methods: Efficacy was measured using OS and progression-free survival (PFS). A discussion was added on the impact of OS based on clinicopathological characteristics, including outcomes in 2L “long-term responder” patients (who achieved response to 2L therapy ⩾6 months) and the evaluation of blood biomarkers. Results: Treatment sequencing has been demonstrated to enhance OS in patients with HER2-positive ABC, with a median OS of 34 months. This effect is more pronounced among long-term responders (37 months), particularly those without central nervous system (CNS) involvement, as compared with those with CNS metastases (51 vs 34 months). Blood biomarkers were not found to be prognostic indicators for either PFS or OS. Conclusions: Treatment sequencing has been demonstrated to enhance OS in LATAM patients with HER2-positive ABC. This study did not identify any prognostic blood biomarkers. These outcomes could influence the selection criteria for patients to receive treatment sequencing in countries without full access to innovative oncological therapies.https://doi.org/10.1177/11782234251342477 |
| spellingShingle | Guillermo Valencia Patricia Rioja Olenka Peralta Miguel Chirito Raúl Mantilla Carlos Castañeda Zaida Morante Hugo Fuentes Tatiana Vidaurre Mónica Calderón Silvia Neciosup Henry L Gómez Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM) Breast Cancer: Basic and Clinical Research |
| title | Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM) |
| title_full | Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM) |
| title_fullStr | Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM) |
| title_full_unstemmed | Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM) |
| title_short | Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM) |
| title_sort | real world experience of her2 positive advanced breast cancer abc treatment and evaluation of blood biomarkers in a public institution in latin america latam |
| url | https://doi.org/10.1177/11782234251342477 |
| work_keys_str_mv | AT guillermovalencia realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT patriciarioja realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT olenkaperalta realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT miguelchirito realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT raulmantilla realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT carloscastaneda realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT zaidamorante realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT hugofuentes realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT tatianavidaurre realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT monicacalderon realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT silvianeciosup realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam AT henrylgomez realworldexperienceofher2positiveadvancedbreastcancerabctreatmentandevaluationofbloodbiomarkersinapublicinstitutioninlatinamericalatam |